Ocugen announced the appointment of Dr. Huma Qamar as Chief Medical Officer. Prior to joining Ocugen, Dr. Qamar was Senior Vice President, Head of R&D at FSD Pharma-demonstrating her commitment to advancing scientific innovation and pharmaceutical development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCGN:
- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
- Ocugen announces dosing completion of Cohort 1 in OCU410 Phase 1/2 trial
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
- Ocugen to Present at Investing in Cures Summit
- Ocugen announces availability of Clinical Showcase webcast
